-
Mashup Score: 7
Apply now Work type: University Tenure Line Location: Stanford University Categories: School of Medicine The Division of Radiation Therapy in the Department of Radiation Oncology at Stanford University seeks a board eligible or board certified radiation oncologist with either a MD/PhD or a MD to join the Department as an Assistant Professor or Associate Professor in the University…
Source: facultypositions.stanford.eduCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Can an annual blood test find cancer while it’s curable? - 2 year(s) ago
Blood tests that screen people for many kinds of cancer are starting to enter the clinic — causing controversy.
Source: The Mercury NewsCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @mercnews: Can an annual blood test find cancer while it’s curable? https://t.co/GjOClvxG6B
-
-
Mashup Score: 6Webprogram Unavailable - 3 year(s) ago
Webprogram is no longer available Please click HERE if you are not redirected in 5 seconds.
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @AshAlizadeh: 0709: #ctDNA identifies #FollicularLymphoma Progenitors w @schroersmartin @SRoulland @max_diehn https://t.co/i3x66iMNc4…
-
-
Mashup Score: 0CNAPS 2022 – May 16-18, 2022 - 3 year(s) ago
As chairs of the local organizing committee, it is our pleasure to announce initial program details of CNAPS XII: the 12th biennial meeting on Circulating Nucleic Acids in Plasma and Serum. The meeting will take place in-person at the Grand Hyatt Hotel in San Francisco, on May 16-18, 2022. We will have a virtual option available, but strongly encourage attendance in person to take advantage…
Source: cnaps2022.comCategories: Hem/Oncs, Latest HeadlinesTweet-
It has been a pleasure to organize the CNAPS 2022 (https://t.co/IkKmJlr2E1) meeting with @StephenQuake. The meeting will feature many of the leaders in the cell-free nucleic acids field and I can't wait to hear about all of their exciting new work starting tomorrow afternoon! https://t.co/MsNPBXWync
-
-
Mashup Score: 4Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease - 4 year(s) ago
Growing evidence demonstrates that circulating tumor DNA (ctDNA) minimal residual disease (MRD) following treatment for solid tumors predicts relapse. These results suggest that ctDNA MRD could identify candidates for adjuvant therapy and measure response to such treatment. Importantly, factors such as assay type, amount of ctDNA release, and technical and biological background can affect ctDNA…
Source: Cancer DiscoveryCategories: Hem/Oncs, Latest HeadlinesTweet-
For those who haven’t seen it yet, I’m excited to share our recent review on ctDNA #MRD in @CD_AACR (https://t.co/4XRZjqPTsf). See the nice tweetorial by @everettmoding below for a summary. We hope it will be useful for others wanting to learn more about this exciting field! https://t.co/9cripBrxXl
-
-
Mashup Score: 0Enhanced detection of minimal residual... - Nature Biotechnology - 4 year(s) ago
Circulating tumor-derived DNA (ctDNA) is an emerging biomarker for many cancers, but the limited sensitivity of current detection methods reduces its utility for diagnosing minimal residual disease. Here we describe phased variant enrichment and detection sequencing (PhasED-seq), a method that uses multiple somatic mutations in individual DNA fragments to improve the sensitivity of ctDNA…
Source: www.nature.comCategories: Latest Headlines, Oncologists1Tweet-
Excited to share our manuscript (https://t.co/6dPawyrlkw) re. PhasED-Seq, a new #ctDNA #MRD detection approach with ~50-100x times better analytical sensitivity than prior methods. See excellent tweetorial below by @AshAlizadeh for details https://t.co/61gngGHekH
-
-
Mashup Score: 0Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer - 4 year(s) ago
Diehn and colleagues report that assaying circulating DNA in patients receiving chemoradiation therapy for non-small-cell lung cancer could identify the patients most likely to benefit from consolidation immunotherapy.
Source: Nature CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
@n8pennell Getting there! This further validates the studies below demonstrating the strong prognostic value of ctDNA MRD in localized NSCLC. Furthermore, at least retrospectively, systemic therapy appears to be able to improve outcomes of some ctDNA MRD+ pts (https://t.co/sQP6ZGOeBs) https://t.co/xwIjGGri3C
-
RT @StanfordRadOnc: Open Faculty Position: Physician Scientist in Radiation Oncology https://t.co/Ag4pZe0rfC https://t.co/PUx6ajn0EW